Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Moderna says its mRNA Access program could help with the next pandemic

By Brian Buntz | March 17, 2022

mRNA Access

Image courtesy of Moderna

Moderna’s mRNA Access program (Nasdaq: MRNA) enables researchers to use its mRNA technology platform for research projects related to emerging and neglected infectious diseases.

“It takes a community of scientists and disease experts to develop novel vaccines to tackle our greatest public health threats,” said Hamilton Bennett, Moderna’s senior director, vaccine access and partnerships.

“mRNA Access was born of the idea that we are stewards of our platform, and by allowing researchers to access that platform and leverage the preclinical, clinical, regulatory and manufacturing capabilities that we’ve created, we could accelerate the development of novel vaccines,” Bennett said.

To prepare for future pandemics, the company is keeping tabs on known and emerging pathogens that pose a considerable risk with the potential for devastating impact on lives around the globe.

Before the pandemic, Moderna had mRNA development candidates for various indications, including infectious diseases such as Cytomegalovirus (CMV) and Zika.

It was Spikevax, the company’s COVID-19 vaccine, that showed that its mRNA platform could enable the rapid development of safe and efficacious vaccines.

Moderna hopes that mRNA Access will complement its development efforts and attract talented scientists and disease experts who can translate their understanding of the immune markers of protection into effective mRNA-based vaccines.

“Moderna is interested in collaborating with scientists who have novel approaches to inducing these protective responses, as well as those that see an opportunity to improve on an existing approach by using mRNA,” a Moderna spokesperson said.

The company’s global public health portfolio aims to address known infectious diseases of significant impact. Moderna is also working on preparing for the next emerging threat, which the company calls ‘Disease X.'”

While the company’s current clinical portfolio includes vaccines targeting COVID-19, HIV, Nipah and Zika, Moderna will focus on other pathogens such as tuberculosis, malaria and dengue by 2025.

“Some of the priority pathogens have epidemic potential like Ebola, Nipah and MERS, but they are also prototypes for related pathogens,” a Moderna spokesperson said. “The prototype vaccine approach learns from vaccines developed against representative viruses to rapidly adapt to tackle other related pathogens, in this way, preparing for Disease X. The value of this prototype vaccine approach was demonstrated when early research on SARS-CoV-1 and MERS enabled Moderna’s rapid response to SARS-CoV-2.”


Filed Under: Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, Ebola, HIV, infectious diseases, MERS, Moderna, mRNA Access, Nipah, Zika
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE